Clinical Trial Update: Rituximab in Primary Lymphocyte Predominant Hodgkin´s Disease(RIPL) [Phase 2]

View source ↗

Summary

Phase 2 clinical trial of Rituximab for Lymphocyte Predominant Hodgkin's Lymphoma (LPHD) has completed. The study is associated with the University of Cologne.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Lymphocyte Predominant Hodgkin Lymphoma

Drugs mentioned

• Rituximab (rituximab)

Snippet

Sponsor: University of Cologne | Conditions: Lymphocyte Predominant Hodgkin´s Lymphoma (LPHD) | Phase 2 | Status: COMPLETED